Appendix 4E - Preliminary Final Report 30 June 2017
Filed with ASX · · 49 pages · English
Sydney, Australia – 24 August 2017:OncoSil Medical Ltd (ASX: OSL) (Oncosilor the Company), a late stage medical devices company focused on localised treatments for patients with pancreatic and liver cancer, is pleased to report its financial results for the full year ended 30 June 2017 (the Financial Report) and its Appendix 4E. All financial results are in Australian dollars and are audited. High
Earlier from OncoSil Medical
- First UK subject recruited
- CE Mark & Quarterly Activity Update
- Second subject recruited at Monash Health Melbourne
- Appendix 4C and Quarterly update
- First OncoSil Device Implantation procedure completed
Later from OncoSil Medical
- Progress update on Global Pancreatic Cancer Clinical Study
- R&D Refund
- Positive Early Study Results Presented at EANM Congress
- Appendix 3C - Employee Loan Share Buy Back
- Additional Receipt of $0.6m R&D Tax Incentive Refund
Follow OncoSil Medical into a list and get an email when it puts out news.
Follow OncoSil Medical